FI81810C - Förfarande för framställning av mukopolysackarider med hög antitrombot isk aktivitet - Google Patents
Förfarande för framställning av mukopolysackarider med hög antitrombot isk aktivitet Download PDFInfo
- Publication number
- FI81810C FI81810C FI854073A FI854073A FI81810C FI 81810 C FI81810 C FI 81810C FI 854073 A FI854073 A FI 854073A FI 854073 A FI854073 A FI 854073A FI 81810 C FI81810 C FI 81810C
- Authority
- FI
- Finland
- Prior art keywords
- mps
- usp
- process according
- compositions
- titers
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 24
- 229920002683 Glycosaminoglycan Polymers 0.000 title claims description 12
- 230000002785 anti-thrombosis Effects 0.000 title claims description 5
- 239000000203 mixture Substances 0.000 claims description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- 229920000669 heparin Polymers 0.000 claims description 21
- 229960002897 heparin Drugs 0.000 claims description 21
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 20
- 239000000047 product Substances 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000003960 organic solvent Substances 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 7
- 238000005194 fractionation Methods 0.000 claims description 7
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 4
- 230000001858 anti-Xa Effects 0.000 claims description 4
- 238000002474 experimental method Methods 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000005995 Aluminium silicate Substances 0.000 claims description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 230000014508 negative regulation of coagulation Effects 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 229910021653 sulphate ion Inorganic materials 0.000 claims description 3
- MCHWWJLLPNDHGL-KVTDHHQDSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-3,4-diol Chemical compound OC[C@H]1O[C@H](CO)[C@@H](O)[C@@H]1O MCHWWJLLPNDHGL-KVTDHHQDSA-N 0.000 claims description 2
- LKAPTZKZHMOIRE-KVTDHHQDSA-N (2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolane-2-carbaldehyde Chemical compound OC[C@H]1O[C@H](C=O)[C@@H](O)[C@@H]1O LKAPTZKZHMOIRE-KVTDHHQDSA-N 0.000 claims description 2
- 108010074860 Factor Xa Proteins 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- LKAPTZKZHMOIRE-UHFFFAOYSA-N chitose Natural products OCC1OC(C=O)C(O)C1O LKAPTZKZHMOIRE-UHFFFAOYSA-N 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 239000001103 potassium chloride Substances 0.000 claims description 2
- 235000011164 potassium chloride Nutrition 0.000 claims description 2
- 239000011541 reaction mixture Substances 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- -1 HCl or CH 3 COOH Chemical class 0.000 description 5
- 230000015271 coagulation Effects 0.000 description 5
- 238000005345 coagulation Methods 0.000 description 5
- 229910017604 nitric acid Inorganic materials 0.000 description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 108010000499 Thromboplastin Proteins 0.000 description 2
- 102000002262 Thromboplastin Human genes 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000012691 depolymerization reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 108010074864 Factor XI Proteins 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 235000005811 Viola adunca Nutrition 0.000 description 1
- 240000009038 Viola odorata Species 0.000 description 1
- 235000013487 Viola odorata Nutrition 0.000 description 1
- 235000002254 Viola papilionacea Nutrition 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical class [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 229910001867 inorganic solvent Inorganic materials 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Materials Engineering (AREA)
- Biochemistry (AREA)
- Polymers & Plastics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Saccharide Compounds (AREA)
Claims (10)
1. Förfarande för framställning av mukopolysackarider, dvs MPS med hög antitrombotisk aktivitet, kännetecknat därav, att man med nämnda förfarande utför ätminstone ett fraktioneringssteg pä mukopolysackaridsammansättningar (1), som i huvudsak bestär av MPS-kedjor, vars molekylvikt (MW) är ca 1800-8000 dalton och YW/USP-titernas förhällande är högre än hos heparin, i avsikt att frän ifrägavarande raukopoly-sackaridsammansättningar selektivt separera ätminstone huvud-delen av de kedjor, vars MW är lägre än 2000, samt de kedjor vars MW är högre, men sulfathalten lägre än heparins blandningskedjornas genomsnittliga sulfathalt, och ätervinna de fraktioner, i vilka de nämnda kedjorna saknas, dä de nämnda fraktionerna har ett lägre YW/USP-titerförhällande än de nämnda mukopolysackaridsammansättningarna (1), samt en högre USP-titer.
2. Förfarande enligt patentkrav 1 kännetecknat därav, att fraktioneringen utförs med en blandning av vatten ; och ett organiskt lösningsmedel, innehällande ett oorganiskt sait, da lösningsmedlet valts bland de lösningsmedel, i vilka ätminstone huvuddelen av de önskade produkterna är selektivt olösliga.
3. Förfarande enligt patentkrav 2, kännetecknat därav, att det organiska lösningsmedlet är en alkohol, särskilt etanol.
4. Förfarande enligt patentkrav 2, kännetecknat ” därav, att det oorganiska saltet är särskilt natrium- eller kaliumklorid eller nägot annat sait som blandar sig med det använda organiska lösningsmedlet.
5. Förfarande enligt patentkrav 2, kännetecknat därav, att reaktionsblandningens pH justeras tili ett surt värde. Il 13 Β16Ί0
6. Förfarande enligt patentkrav 2, kännetecknat därav, att pH justeras tili ett värde under 4.
7. Förfarande enligt patentkrav 5, kännetecknat därav, att förhallandet mellan YW-titern och USP-titern i de MPS-sanunansättningar som används i fraktionsförfarandet är ätminstone ca 10 och YW-titern är ca 200-250 u/mg.
8. Förfarande enligt patentkrav 5, kännetecknat därav, att fraktioneringen utförs med hjälp av ett organiskt lösningsmedel, som tilläter en selektiv utfällning av sädana MPS vars YW/USP-titerförhällande är lägre än 10, fördelaktigast ca 6-3 och särskilt kring 4.
9. Förfarande enligt patentkrav 2, kännetecknat därav, att man framställer en 5% (vikt/volym) MPS-lösning i vatten, som innehäller 10 g/1 etanol och efter en pH-justering tili 3,8 far till ständ en fraktionering genom att tillsätta en volym etanol och tillvarata den fälining som bildats.
10. Förfarande enligt patentkrav 1, kännetecknat därav, att de använda MPS-sammansättningarna i den reduceran- : de ändan har en 2,5-anhydromannostrukturenhet, som fördel- aktigast valts ur en grupp bestäende av 2,5-anhydromannos, 2,5-anhydromannitol eller 2,5-anhydromannonsyra.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8415978A FR2572080B1 (fr) | 1984-10-18 | 1984-10-18 | Procede de preparation de compositions de mucopolysaccharides dotees d'une activite antithrombotique elevee, les compositions obtenues et leur application en tant que medicaments |
| FR8415978 | 1984-10-18 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| FI854073A0 FI854073A0 (fi) | 1985-10-18 |
| FI854073L FI854073L (fi) | 1986-04-19 |
| FI81810B FI81810B (fi) | 1990-08-31 |
| FI81810C true FI81810C (sv) | 1990-12-10 |
Family
ID=9308784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI854073A FI81810C (sv) | 1984-10-18 | 1985-10-18 | Förfarande för framställning av mukopolysackarider med hög antitrombot isk aktivitet |
Country Status (18)
| Country | Link |
|---|---|
| JP (1) | JPS61101502A (sv) |
| KR (1) | KR920006002B1 (sv) |
| AR (1) | AR243539A1 (sv) |
| CS (1) | CS270420B2 (sv) |
| DD (1) | DD239798A5 (sv) |
| DZ (1) | DZ844A1 (sv) |
| EG (1) | EG17478A (sv) |
| FI (1) | FI81810C (sv) |
| FR (1) | FR2572080B1 (sv) |
| HU (1) | HU197931B (sv) |
| IL (1) | IL76701A (sv) |
| MA (1) | MA20554A1 (sv) |
| NO (1) | NO166369C (sv) |
| PL (1) | PL146770B1 (sv) |
| SU (1) | SU1570651A3 (sv) |
| UA (1) | UA5929A1 (sv) |
| YU (1) | YU45285B (sv) |
| ZA (1) | ZA857902B (sv) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69005251T2 (de) * | 1989-10-04 | 1994-05-05 | Akzo Nv | Sulfatierte Glykosaminoglykuronane mit antithrombotischer Wirkung. |
| DK3144325T3 (da) * | 2010-09-14 | 2021-01-25 | Univ Miyazaki | Heparin med høj renhed og fremstillingsfremgangsmåde dertil |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2440376A1 (fr) * | 1978-11-06 | 1980-05-30 | Choay Sa | Composition mucopolysaccharidique ayant une activite regulatrice de la coagulation, medicament la contenant et procede pour l'obtenir |
| FR2478646A2 (fr) * | 1980-03-20 | 1981-09-25 | Choay Sa | Composition mucopolysaccharidique ayant une activite regulatrice de la coagulation, medicament la contenant et procede pour l'obtenir |
| FR2495935A1 (fr) * | 1980-12-15 | 1982-06-18 | Choay Sa | Fractions mucopolysaccharidiques possedant des proprietes biologiques, leur procede de preparation et leur application en tant que medicaments |
| FR2503714B1 (fr) * | 1981-04-10 | 1986-11-21 | Choay Sa | Procede d'obtention de mucopolysaccharides biologiquement actifs, de purete elevee, par depolymerisation de l'heparine |
-
1984
- 1984-10-18 FR FR8415978A patent/FR2572080B1/fr not_active Expired
-
1985
- 1985-02-27 KR KR1019850007686A patent/KR920006002B1/ko not_active Expired
- 1985-10-13 EG EG650/85A patent/EG17478A/xx active
- 1985-10-14 DZ DZ850225A patent/DZ844A1/fr active
- 1985-10-14 IL IL76701A patent/IL76701A/xx not_active IP Right Cessation
- 1985-10-15 ZA ZA857902A patent/ZA857902B/xx unknown
- 1985-10-15 AR AR85301959A patent/AR243539A1/es active
- 1985-10-17 SU SU853965564A patent/SU1570651A3/ru active
- 1985-10-17 DD DD85281840A patent/DD239798A5/de not_active IP Right Cessation
- 1985-10-17 YU YU1660/85A patent/YU45285B/xx unknown
- 1985-10-17 UA UA3965564A patent/UA5929A1/uk unknown
- 1985-10-18 JP JP60233118A patent/JPS61101502A/ja active Granted
- 1985-10-18 PL PL1985255832A patent/PL146770B1/pl unknown
- 1985-10-18 MA MA20778A patent/MA20554A1/fr unknown
- 1985-10-18 NO NO854154A patent/NO166369C/no not_active IP Right Cessation
- 1985-10-18 HU HU854046A patent/HU197931B/hu unknown
- 1985-10-18 CS CS857467A patent/CS270420B2/cs not_active IP Right Cessation
- 1985-10-18 FI FI854073A patent/FI81810C/sv not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA857902B (en) | 1987-03-25 |
| EG17478A (en) | 1991-03-30 |
| DZ844A1 (fr) | 2004-09-13 |
| JPH0552841B2 (sv) | 1993-08-06 |
| HU197931B (en) | 1989-06-28 |
| FI854073L (fi) | 1986-04-19 |
| KR860003275A (ko) | 1986-05-21 |
| YU166085A (en) | 1988-06-30 |
| CS270420B2 (en) | 1990-06-13 |
| SU1570651A3 (ru) | 1990-06-07 |
| UA5929A1 (uk) | 1994-12-29 |
| JPS61101502A (ja) | 1986-05-20 |
| AR243539A1 (es) | 1993-08-31 |
| KR920006002B1 (ko) | 1992-07-25 |
| NO854154L (no) | 1986-04-21 |
| YU45285B (en) | 1992-05-28 |
| NO166369C (no) | 1991-07-17 |
| CS746785A2 (en) | 1989-11-14 |
| FR2572080B1 (fr) | 1987-06-26 |
| PL146770B1 (en) | 1989-03-31 |
| IL76701A (en) | 1990-09-17 |
| IL76701A0 (en) | 1986-02-28 |
| FI854073A0 (fi) | 1985-10-18 |
| FR2572080A1 (fr) | 1986-04-25 |
| FI81810B (fi) | 1990-08-31 |
| DD239798A5 (de) | 1986-10-08 |
| MA20554A1 (fr) | 1986-07-01 |
| PL255832A1 (en) | 1987-02-09 |
| HUT38657A (en) | 1986-06-30 |
| NO166369B (no) | 1991-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2099350C1 (ru) | Ассоциаты депротонированной гиалуроновой кислоты, способ их получения, фармацевтическая композиция, содержащая ассоциаты депротонированной гиалуроновой кислоты, и способ ее получения | |
| CA1327968C (fr) | Heparines de bas poids moleculaire, a structure reguliere leur preparation et leurs applications biologiques | |
| JP5371167B2 (ja) | 抗脈管形成活性を有し、かつ、抗凝固作用がない、部分脱硫酸グリコサミノグリカンの誘導体 | |
| US5008253A (en) | Sulfoamino derivatives of chondroitin sulfates of dermatan sulfate and of hyaluronic acid and their pharmacological properties | |
| US4686288A (en) | Process for preparing mucopolysaccharide compositions having high antithrombotic activity, the compositions obtained and their use as medicaments | |
| de Belder et al. | Preparation and properties of fluorescein-labelled hyaluronate | |
| FI94534B (sv) | Förfarande för framställning av nya heparinderivat | |
| DE69228362T2 (de) | Hochmolekulare, N,O-sulfatierte Heparosane; Verfahren zu deren Herstellung und diese enthaltende Arzneimittel | |
| HK1003003B (en) | Novel compositions containing hyaluronic acid associates and a process for preparing same | |
| JP2011503001A (ja) | 非抗凝固性多糖組成物 | |
| IE52878B1 (en) | Process for the preparation of biologically active mucopolysaccharides of high putity by the controlled depolymerisation of heparin | |
| DE68916878T2 (de) | Selektiv O-acylierte Glycosaminoglykane. | |
| US4788307A (en) | Oligosaccharidic fractions devoid or practically devoid of antithrombotic activity | |
| McAllister et al. | Heparin metabolism: isolation and characterization of uroheparin | |
| Gandy et al. | Molecular determinants of the interaction between HSV-1 glycoprotein D and heparan sulfate | |
| FI81810C (sv) | Förfarande för framställning av mukopolysackarider med hög antitrombot isk aktivitet | |
| IT9021909A1 (it) | Procedimento per la preparazione di epossi-eparidi prodotti ottenuti e composizioni farmaceutiche che li contengono | |
| US20100075922A1 (en) | Heparins including at least one covalent bond with biotin or a biotin derivative, method for preparing same and use thereof | |
| JP2714718B2 (ja) | 新規硫酸化多糖及びその薬学的に許容される塩、その製造方法並びにそれを有効成分とする医薬 | |
| Prokopek | The tilorone-induced mucopolysaccharidosis in rats: Biochemical investigations | |
| Cziner et al. | Vacuum ultraviolet circular dichroism of dermatan sulfate: Iduronate ring geometry in solution and solid state | |
| RU2176915C2 (ru) | Полусинтетические сульфаминогепаросансульфаты, имеющие высокую антиметастатическую активность и пониженный геморрагический риск | |
| CN1554671A (zh) | 一种低亚硝酸盐含量的低分子肝素钙的制备方法 | |
| Bonavita et al. | The urinary excretion of heparan sulfate by juvenile-and adult-onset diabetic patients | |
| US5472950A (en) | Compositions containing cobalt hyaluronic acid complex |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Patent granted |
Owner name: SANOFI-SYNTHELABO |
|
| PC | Transfer of assignment of patent |
Owner name: SANOFI-AVENTIS |
|
| MA | Patent expired |